Lilly sells Zepbound KwikPen at same self-pay price as vials, starting at $299 a month

Eli Lilly said on February 23, 2026, that the U.S. Food and Drug Administration approved a label expansion for Zepbound (tirzepatide) to include a four-dose, single-patient-use KwikPen that delivers a full month of treatment in one device ^[1]. The company began selling the pen through LillyDirect at self-pay prices that match its single-dose vials, starting at $299 a month ^[1][2].

The KwikPen is available in all six Zepbound doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg ^[3]. Self-pay prices through LillyDirect are $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg and higher when a patient refills within 45 days under the Zepbound Self Pay Journey Program ^[2][4]. If the refill comes more than 45 days after the previous one, regular prices apply: $499 for 7.5 mg and $699 each for 10 mg, 12.5 mg and 15 mg ^[2][4]. The same $449 purchase offer applies to both the single-dose vial and the KwikPen for the 7.5 mg through 15 mg doses starting February 23, 2026 ^[2]. At every dose, the two formats carry the same self-pay price ^[4].

Pen needles are sold separately for the KwikPen, and needles and syringes are sold separately for the vials ^[4]. Zepbound's label warns that a KwikPen must not be shared with another person, even if the needle has been changed ^[1]. KwikPen devices are already used to deliver Mounjaro, Lilly's diabetes medicine, and are sold in the United Kingdom, Australia, the Middle East and Canada ^[3].

Patients who fill at a retail pharmacy can use the KwikPen Self-Pay Savings Card to get the same self-pay prices ^[5]. The card applies only to the KwikPen, not to the single-dose vials or the single-dose pen ^[5]. Under the card terms, patients pay as low as $299 for 2.5 mg (maximum monthly savings of up to $215), $399 for 5 mg (up to $115), and $449 for 7.5 mg (up to $65) or for 10 mg, 12.5 mg or 15 mg (up to $271) ^[2]. The card can be used for up to 11 fills per calendar year and expires December 31, 2026 ^[2].

Separately, eligible commercially insured patients with coverage pay as low as $25 a month for the single-dose pen ^[2][4]. Some Medicare Part D beneficiaries with a Zepbound prescription for weight management may pay no more than $50 a month under the Medicare GLP-1 Bridge program, subject to eligibility criteria and plan exclusions ^[2].

Lilly says Zepbound was the most prescribed weight management medication in 2025 ^[1]. In the SURMOUNT-1 trial, adults taking 15 mg lost an average of 20.9% of their body weight over 72 weeks, compared with 3.1% for placebo, and in SURMOUNT-5, people taking Zepbound lost an average of 50 pounds (20.2%), compared with 33 pounds (13.7%) for injectable Wegovy (semaglutide) ^[1]. Lilly says more than 1 million patients accessed its treatments through LillyDirect in 2025 ^[1].

Why it matters for patients

For people paying cash, the format decision no longer changes the monthly price at a given dose: a KwikPen and a month of vials are listed at the same amount ^[4]. The lowest maintenance-dose price, $449, depends on refilling within 45 days, and pen needles are an extra purchase ^[2][4]. The savings card is capped at 11 fills a year and expires December 31, 2026, and Lilly says it can change or end the program at any time ^[2]. The card does not apply to the vials or the single-dose pen, so a patient who switches between formats fills under a different set of terms ^[5].

Insurance is separate from self-pay pricing. Lilly says existing Zepbound coverage continues and that commercial CVS Caremark coverage expands on October 1, with some employers reinstating earlier ^[2]. How individual plans treat the KwikPen specifically has not been disclosed. Lilly says self-pay pricing through LillyDirect is at least 50% below the list price of other incretin medicines for obesity ^[1].

What happens next

To keep the $449 price for 7.5 mg and above, patients must complete a refill within 45 days of the delivery or receipt date of their previous fill ^[2][4]. The KwikPen self-pay savings card expires December 31, 2026 ^[2]. Lilly has said self-pay pricing for the KwikPen will also be available at major pharmacies nationwide, in addition to LillyDirect ^[5].